Uniplan Investment Counsel’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.54M Buy
12,531
+2,854
+29% +$977K 0.43% 68
2026
Q1
$3.41M Sell
9,677
-414
-4% -$148K 0.35% 75
2025
Q4
$3.3M Buy
10,091
+2,267
+29% +$719K 0.33% 81
2025
Q3
$2.21M Sell
7,824
-412
-5% -$119K 0.22% 109
2025
Q2
$2.3M Sell
8,236
-684
-8% -$194K 0.23% 100
2025
Q1
$2.78M Sell
8,920
-187
-2% -$55.2K 0.27% 92
2024
Q4
$2.37M Sell
9,107
-427
-4% -$127K 0.22% 97
2024
Q3
$3.07M Sell
9,534
-676
-7% -$221K 0.27% 84
2024
Q2
$3.19M Sell
10,210
-232
-2% -$68.2K 0.29% 80
2024
Q1
$2.97M Sell
10,442
-1,481
-12% -$433K 0.23% 86
2023
Q4
$3.44M Buy
+11,923
New +$3.25M 0.26% 80

Other funds holding AMGN

Uniplan Investment Counsel's AMGN Position: Q2 2026 in Review

Uniplan Investment Counsel increased its Amgen (AMGN) stake by 29% in Q2 2026, buying an estimated $977K and bringing the position to 12,531 shares worth $4.54M. The position accounts for 0.43% of the portfolio, ranked #68.

Uniplan Investment Counsel first reported a position in AMGN in Q4 2023 and has held it in 11 quarters since. 3,164 funds tracked by Wall St. Rank hold AMGN as of Q2 2026.

  • Uniplan Investment Counsel held 12,531 shares of Amgen worth $4.54M as of Q2 2026.
  • Uniplan Investment Counsel bought 2,854 Amgen shares in Q2 2026, an estimated $977K.
  • Amgen made up 0.43% of Uniplan Investment Counsel's portfolio in Q2 2026, its #68 holding.
  • Uniplan Investment Counsel first reported a position in Amgen in Q4 2023 and has held it in 11 quarters since.
  • 3,164 funds tracked by Wall St. Rank held Amgen as of Q2 2026.

Based on Uniplan Investment Counsel's 13F filing for Q2 2026, filed 13 Aug 2026.